Manufacturing and Marketing Approval Granted in Japan for ORLADEYO^® for Pediatric Patients with Hereditary Angioedema
— A new oral treatment option for children aged 2 to under 12 years weighing 15 kg or more —

Notice regarding Approval of a Partial Change to the Marketing Authorization for Sodium Phenylbutyrate for Progressive Familial Intrahepatic Cholestasis (PFIC) Types 1 and 2

OrphanPacific Announces the Launch of Joenja^® (leniolisib) in Japan for the Treatment of APDS in Adults and Pediatric Patients 4 Years of Age and Older

Announcement of Launch in Japan of RAVICTI^® Oral Liquid 1.1 g/mL

OrphanPacific Obtains Marketing Approval in Japan for Leniolisib (Joenja^®) for the Treatment of APDS for adults and pediatric patients 4 years of age and older